Merck, Inc.
🇵🇭Philippines
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3882
- Registration Number
- NCT00092482
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 413
- Registration Number
- NCT00092365
Consistency Lots Vaccine Study (V260-009)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 793
- Registration Number
- NCT00092456
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1997
- Registration Number
- NCT00092391
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 695
- Registration Number
- NCT00092417
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT00092430
Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 151
- Registration Number
- NCT00092469
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 820
- Registration Number
- NCT00092196
A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 652
- Registration Number
- NCT00092079
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Phase 4
Completed
- Conditions
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 866
- Registration Number
- NCT00092183
© Copyright 2024. All Rights Reserved by MedPath